| 322.03 0.8 (0.25%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 389.29 | 1-year : | 454.7 |
| Resists | First : | 333.3 | Second : | 389.29 |
| Pivot price | 319.7  |
|||
| Supports | First : | 313.12 | Second : | 300.64 |
| MAs | MA(5) : | 324.55 |
MA(20) : | 318.49 |
| MA(100) : | 296.14 |
MA(250) : | 319.82 |
|
| MACD | MACD : | 4.6 |
Signal : | 4.7 |
| %K %D | K(14,3) : | 69.1 |
D(3) : | 74.5 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 375.32 | Low : | 243.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ COR ] has closed below upper band by 41.5%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 323.9 - 325.5 | 325.5 - 327.12 |
| Low: | 316.59 - 318.26 | 318.26 - 319.96 |
| Close: | 319.26 - 321.89 | 321.89 - 324.56 |
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Thu, 27 Aug 2026
Cencora Executive VP & Chief Legal Officer Elizabeth Campbell Sells 37% Of Holding - simplywall.st
Wed, 26 Aug 2026
Cencora (COR) Earnings History & Trends - 24/7 Wall St.
Wed, 26 Aug 2026
Cencora Inc (COR) Executive Vice President Elizabeth Campbell Se - GuruFocus
Tue, 25 Aug 2026
Is Cencora (COR) Still Undervalued Following Its Board Resignation News? - Sahm
Mon, 24 Aug 2026
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Mon, 24 Aug 2026
Cencora (NYSE: COR) officer may sell multimillion-dollar stake - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 191 (M) |
| Shares Float | 180 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 5,170 (K) |
| Shares Short P.Month | 5,500 (K) |
| EPS | 13.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.98 |
| Profit Margin | 0.7 % |
| Operating Margin | 1.4 % |
| Return on Assets (ttm) | 3.5 % |
| Return on Equity (ttm) | 96.8 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 69.06 |
| Sales Per Share | 1743.8 |
| EBITDA (p.s.) | 29.08 |
| Qtrly Earnings Growth | 11.8 % |
| Operating Cash Flow | 4,820 (M) |
| Levered Free Cash Flow | 2,040 (M) |
| PE Ratio | 23.88 |
| PEG Ratio | 0.6 |
| Price to Book value | 20.13 |
| Price to Sales | 0.18 |
| Price to Cash Flow | 12.74 |
| Dividend | 0.6 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|